SAN DIEGO, Aug. 10 /PRNewswire/ — BrainCells Inc. (BCI) today announced it has in-licensed a clinical-stage compound from Mitsubishi Pharma Corp. (MPC) that BCI will reposition and develop for the treatment of central nervous system (CNS) diseases, including mood disorders.

MPC extensively developed the compound for another CNS indication, then suspended the program when the drug met safety expectations but did not reach the defined efficacy endpoints. BCI applied its proprietary technology in the area of neurogenesis

To understand the technology of neurogenesis better it is first important to know what the process is. When new neurons get formed in the brain then this is known as neurogenesis. In this process, the neural state cells differentiate. This means that they turn into one or many numbers of specialised cell types. These are formed at specific times and specific regions in the brain. If there are weakening signals in the brain then your doctor may also prescribe to you the SkinVitalissupplement.

The process by which endogenous stem cells in the adult human brain produce new brain tissue, including neurons — to identify different indications for the drug. The company expects to begin development and initiate additional Phase 2 clinical trials of the compound, BCI-540, next year.

“This is indicative of the extensive opportunity that exists for us in the CNS drug development space,” said James A. Schoeneck, BCI’s CEO. “We can screen compounds efficiently for neurogenic properties and pursue the development of these compounds for indications that weren’t part of a licensor’s original plans. The license from MPC provides us with the ability to capitalize on the predictive power of our screening platform, enabling us to develop a novel product for CNS disorders that affect millions of patients.”

“BCI has a unique approach to the identification and development of drugs that can be repositioned for a variety of CNS diseases,” said Akihiro Tobe, managing executive officer of MPC. “We believe that BCI has the right mix of cutting-edge science and development expertise to maximize the opportunity for the compound.”

About Mitsubishi Pharma Corp.

Mitsubishi Pharma Corporation (MPC), a research-driven pharmaceutical company, is the core member in the Mitsubishi Chemical Holdings group, under which Mitsubishi Chemical, a leading chemical company in Japan, and MPC exist as wholly-owned subsidiaries. Formed in 2001 by the merger of Mitsubishi-Tokyo Pharmaceuticals & Welfide Corporation (formerly Yoshitomi), MPC is committed to scientific progress, pharmaceutical advancement and the creation of products that benefit worldwide people’s welfare. Its core therapeutic areas are psychiatric and central nervous system diseases, cardiovascular and metabolic diseases, immunological and respiratory diseases and hepatic diseases. More information about the company can be found by visiting http://www.m-pharma.co.jp/.

About BrainCells Inc.

BrainCells Inc. (BCI) is a San Diego-based drug discovery and development company that is applying proprietary neurogenesis-based technology to identify and reposition compounds for the treatment of central nervous system (CNS) diseases. With its predictive screening platform, BCI can direct the selection and development of neurogenic compounds, increasing the opportunity for successful clinical trials in a variety of CNS indications. For more information, visit http://www.braincellsinc.com.

Read More →
Share:

Savient Pharmaceuticals, Inc. (NASDAQ:SVNT) a specialtypharmaceutical company engaged in developing, manufacturing, andmarketing pharmaceutical products that address unmet medical needs,announced today that it has dosed the first patient in its Phase 3clinical studies of Puricase(R), (PEG-uricase) for the treatment ofpatients with symptomatic gout for whom conventional therapy iscontraindicated or has been ineffective.The two, replicate Phase 3 clinical studies, Gout Outcomes andUric acid Treatment or “GOUT 1″ and “GOUT 2″, are designed to comparethe safety and efficacy of Puricase(R) administered by two-hourintravenous infusion every two weeks or every four weeks versusplacebo infusion, over a six-month period. Each study will randomizeapproximately 100 patients.

Christopher Clement, Chairman and Chief Executive Officer ofSavient Pharmaceuticals, Inc. said, “The start of patient dosingrepresents an important step in moving Puricase(R) towardscommercialization. As we have stated previously, our focus andresources are being devoted towards the development of this promisingdrug for the treatment of severe gout.”

“The two GOUT studies now underway at approximately 60 clinicalsites in the US, Mexico, and Canada incorporate an innovative designand novel methodologies to demonstrate both uric acid control andattainment of clinical outcomes. The first patient was randomized intothe Phase 3 program last month as planned, but because of a requiredrun-in/wash-out period between screening and start of dosing, nopatient received the first study drug dose in May. Achievement offirst patient dosing now, within about one month of FDA’s approval ofour Special Protocol Assessment is an important milestone forvalidating the operational effectiveness of our Phase 3 developmentteam,” said Zeb Horowitz, M.D., Chief Medical Officer and Senior VicePresident. “Our CRO partner, Kendle International, which has beenworking very closely with the Savient team, has a successful trackrecord in the clinical investigation of other biological drugs,particularly those administered by intravenous infusion forrheumatologic diseases. As such, they are ideal collaborators in theclinical development of Puricase (PEG-uricase). ”

Antibodies help in treating cancer patients. The monoclonal antibodies are produced in the laboratory. Similarly there are lab produced supplements like Dietonusthat helps to lose weight.

The antibodies to treat cancer are molecules that are engineered to serve as a substitute antibody. It helps to enhance, restore and mimic the attack on the cancer cells by the immune system.

ABOUT GOUT

According to the National Institutes of Health, gout accounts forapproximately 5 percent of all cases of arthritis and is one of themost painful rheumatic diseases. There an estimated 5 millionAmericans with gout, including perhaps 25,000-100,000 patients forwhom conventional therapy is contraindicated or has been ineffective.Gout results from deposits of needle-like crystals of uric acid inconnective tissue and in the joints. These deposits lead toinflammatory arthritis, which causes joint swelling, redness, heat,pain, and stiffness and damage to the affected joints. In patients forwhom conventional therapy is contraindicated or has been ineffective,the disease can become chronic, progressively worsen and causedebilitating flares of pain and swelling, development of tophi, lossof joint functionality, renal disease and kidney stones.

ABOUT PURICASE(R), (PEG-URICASE)

Puricase(R) is a chemically modified form of recombinant uricase,based on mammalian sequences, under development by Savient forindividuals with symptomatic gout who cannot be treated adequately byconventional therapies. Puricase(R), (PEG-uricase) has successfullycompleted Phase 1 and 2 studies, proving to be safe and well-toleratedwith few adverse events. Savient licensed exclusive, worldwide rightsto the technologies related to Puricase(R) (PEG-uricase) from DukeUniversity (“Duke”) of North Carolina and Mountain ViewPharmaceuticals, Inc. (“MVP”), a California corporation. Dukedeveloped the recombinant porcine urate oxidase and MVP developed thePEGylation technology. MVP and Duke were granted U.S. and foreignpatents covering the licensed technology. Puricase(R) is a registeredtrademark of Mountain View Pharmaceuticals, Inc.

ABOUT SAVIENT PHARMACEUTICALS

Based in East Brunswick, New Jersey, Savient Pharmaceuticals,Inc., is an emerging specialty pharmaceuticals company and is engagedin developing, manufacturing and marketing pharmaceutical productsthat address unmet medical needs in both niche and broader markets.The Company’s lead product development candidate, Puricase(R)(PEG-uricase), for the treatment of refractory gout has reportedpositive Phase 1 and 2 clinical data. Savient’s experienced managementteam is committed to advancing its pipeline and expanding its productportfolio by in-licensing late stage compounds and exploringco-promotion and co-development opportunities that fit the Company’sexpertise in specialty pharmaceuticals and initial focus inrheumatology. Savient markets its product Oxandrin(R) (oxandrolone,USP) in the United States. The Company’s subsidiary, RosemontPharmaceuticals Ltd., develops, manufactures, and markets through itsown sales force oral liquid formulations of prescription products forthe UK pharmaceutical market. Rosemont’s product portfolio includesover 100 liquid formulations primarily targeting the geriatricpopulation. Puricase(R) is a registered trademark of Mountain ViewPharmaceuticals, Inc. Further information on the Company can beaccessed by visiting: www.savientpharma.com .

Read More →
Share:

In a discovery that could have sweeping implications for pharmaceuticals of the future, scientists are reporting today that the long-observed jiggle of proteins is not just nervous energy but a carefully orchestrated dance that brings them together.

Virtually all medicines work by interacting with proteins – tiny organic molecules that trigger all bodily functions, from the blinking of an eye to inflammation that causes pain.

Have you wondered how medicines work in your body? Also have you ever wanted to know how Senomaxhelps to firm your breast? We swallow many medicines which are taken as a liquid or as a pill. Once the medicine is swallowed the digestive juices that are present in the stomach starts to break down. This allows the medicine to pass through the blood stream and the blood caries it to other parts of the body for the medicine to work.

For years, researchers have routinely relied on three-dimensional images of proteins to design custom-fitted pharmaceuticals.

The approach has had less success than some had expected.

In the paper being published today in the journal Nature, University of Pennsylvania biophysicist A. Joshua Wand outlines why three dimensions have not been sufficient.

An image does not capture movement, Wand said, and the specific nature of that movement – like the allure of a mating dance – is key to how proteins work.

“If we want to revive drug design in pharmaceutical industries or universities, there has to be a new realization of this in the design process,” said Erik Zuiderweg, a biophysicist at the University of Michigan-Ann Arbor who was not involved in the study.

Central to creating any new medicines is the way proteins operate – through connection.

“All proteins do in life is bind [to] another protein,” said Wand, principal investigator of the study.

And most of life’s functions are controlled by proteins. When the body needs food, proteins couple in a chain reaction that produces the feeling of hunger; another set of chain reactions triggers digestion, and on and on.

Certain proteins can cause disease or unpleasant symptoms. In those cases, drugs may limit a protein’s potency by blocking its ability to bind and participate in the chain reaction.

Aspirin, for example, eases pain by gumming up a protein called COX-2. Neutering this one protein breaks down the whole network that regulates inflammation. Headache cured.

Historically, new drugs have emerged through trial and error – throw various compounds at a protein in the lab and see what sticks.

In the 1980s, as more and more 3-D blueprints of protein structures became available, pharmaceutical designers tried to do more than just take shots in the dark. In theory, since the images illuminate all a protein’s interesting bits, making a drug should be as easy as building the right piece to fit into a puzzle.

The process is called “rational drug design.” But apart from a few successes – an HIV protease inhibitor, for one – “it has failed,” said Zuiderweg, who worked on drug discovery at Abbott Laboratories from 1984 to 1991.

Since the early ’90s, drugmakers have used a method called high-throughput screening, which involves jamming thousands of puzzle pieces – potential drugs – into computer models of proteins to find the best fits. This, too, has not been particularly fruitful.

“Several drug companies I have contact with,” Zuiderweg said yesterday, “have given up on this. . . . Currently they are sitting empty-handed.”

The problem is that the static images of proteins show “only one part,” Wand said. “The other part has been hidden for a long time.”

The hidden part, movement, is known to scientists as entropy.

For some time, researchers have been able to peer into a closed system, such as a beaker of water, and measure all the motion within. But there has been no way to tease out the contributions from each individual component.

In a breakthrough that set the stage for his latest discovery, Wand’s team several years ago developed a strategy to zoom in on the entropy of just the protein.

“What came out of this was remarkable and totally unexpected,” he said.

Wand used a tool called Nuclear Magnetic Resonance spectroscopy (NMR). Like hospital MRI, its offspring, NMR uses strong magnets, but it looks closely at tiny jittering molecules rather than at people’s insides.

NMR was performed on calmodulin, a calcium-binding protein that serves multiple functions, contacting hundreds of other proteins in the process.

“It’s hard to imagine one key binding 300 different locks,” Wand said, “but if the key can change its shape, then maybe.”

First the researchers used NMR to examine calmodulin’s dance with itself. Then they measured how its dance steps changed when it snagged each of six different partners. Like a molecular Fred Astaire, each of calmodulin’s binding partners elicited a different dance.

The aha! moment came when the scientists noticed that the way calmodulin’s dance changed with each partner protein seemed to dictate the energy of the system as a whole: calmodulin, its binding partner and the surrounding water.

“That means the entropy is important or else it would have been randomized by evolution,” Wand said.

The next question for Wand is whether this feature of calmodulin is shared by all proteins. Based on some preliminary analysis, “we’ve found the correlation is consistent for other proteins,” said Michael Marlow, a coauthor and postdoctoral fellow in Wand’s lab.

If this holds up, then it could be widely exploited in the development of new medicines.

“We are certainly looking at this and thinking of ways we may be able to incorporate it,” said Jonathan Moore, senior director of structural biology at Vertex Pharmaceuticals Inc., a biotech in Cambridge, Mass. “While the method is very clever and really interesting, it is still the first step.”

Zuiderweg predicts that if hard-to-get government grants for the most basic science are available, the findings could be incorporated into the search for new pharmaceuticals “in half a decade or so.”

“If nature can capitalize on it,” he said, “the pharmaceutical industry certainly can.”

Read More →
Share:

Targeted cancer drug developer Ruga negotiated rights to Selexagen Therapeutics’ RAF kinase program. The firm claims the acquired technology addresses the drawbacks to BRAF inhibition as an approach to cancer therapy.

Cancers are of many kinds and also are the differenttreatments for cancer. Thetype of treatment that your doctor will suggest is dependent on the type of cancer and also the stage to which the cancer has advanced. Some may be asked to undergo a single treatment while others may have to take a combination of manytreatments.

The treatment could be chemotherapy, surgery radiation therapy, targeted therapy, immune therapy or hormone therapy. If you are sufferingfromdiabetes too then you may want to click for more info.

So talking about cancer you will have to learn a lot andthink about. It is normal that you may feel confused andoverwhelmed. You should discuss the treatment plans with your doctor andlearn all that you can before takingany decision. The goal of the doctor is to offer you a treatment plan that can help to cure cancer allowing you to live a normal life span. This may be possible but that is dependent on your individual case. If the doctorwill not be able to cure the cancer then he may suggesttreatments to shrink thecancer to slow its growth. This will let you live without symptoms for along time.

Data has demonstrated that BRAF inhibition can actually induce adaptation in RAS-activated cells and promote the development of secondary skin lesions and RAS-mutated tumor growth, while triggering the paradoxical mitogen-activated protein kinase (MAPK) pathway may in addition be responsible for an escape route for drug resistance.

Ruga is exploiting a suite of in vitro and in vivo technologies to discover and develop drugs that modulate tumor-selective adaptive responses, including tumor metabolism pathways, autophagy, the endoplasmic reticulum (ER) stress response and tumor microenvironment adaptation pathways. In 2010 the firm obtained an exclusive worldwide license to a platform technology developed at Stanford University for targeting tumor-specific adaptive responses mediated through tumor metabolism and ER stress pathways.

The RAF kinase licensed in from Selexagen will complement Ruga’s existing pipeline by targeting an additional pathway used by tumor cells to proliferate, adapt, and metastatize, the firm claims. “Ruga is well positioned to meet its goal of bringing three programs into clinical development in 2013,” comments Ray Tabibiazar, M.D., president and CEO.

Selexagen is exploiting molecular modelling and structure-based drug design technologies to develop targeted cancer

Read More →
Share:

Janssen Pharmaceuticals reported Phase III results demonstrating the efficacy of Nucynta® ER (extended release tapentadol) in managing pain associated with chronic diabetic peripheral neuropathy (DPN). Janssen says the data is consistent with that of a separate study reported in 2011 in patients with DPN.

Diabetes is a common condition but it is a slow killer. Type 1 diabetes occurs when the body’s immune system, that is the system that fights infections, destroys and attacks the beta cells in the pancreas that produce insulin.

It is believed that type 1 diabetes is passed down because of genes and some environmental factors. It could also be because of virus that may trigger this disease. There are studies going on to understand the causes of type 1 diabetes and the possible ways to prevent or to slow down the diseases. If you suffer from diabetes and complain of pain on your foot then visitthis site for help.

The other type or diabetes is type 2 diabetes. This is caused because of genes as well as your lifestyle factors. The main cause of type 2 diabetes is lack of physical activity, obesity and being overweight. Extra weight leads to resistance of insulin and this is common in those who suffer from type 2 diabetes. The location where fat is accumulated also matters.

Nucynta ER is a centrally acting analgesic that acts as both a mu-opioid receptor agonist and norepinephrine reuptake inhibitor. The drug is classified as a Schedule II controlled substance, and is indicated for managing moderate-to-severe chronic pain in adults requiring continuous, 24-hour opioid analgesia for extended periods.

The latest Phase III study, in patients with moderate-to-severe chronic painful DPN, included two treatment phases. The initial open-label stage involved a three-week titration period during which the tapentadol ER dose was optimized for each patient. During the second, double-blind maintenance phase, 318 patients who had demonstrated pain intensity reduction of at least one point during the open-label phase were randomized either to continue taking their optimized dose of tapentadol ER, or placebo for 12 weeks. The results showed that while patients switched to placebo demonstrated an average increase in pain intensity of 1.3 points, pain reduction was maintained in patients remaining on tapentadol ER.

Tapentadol was originally discovered by Grünenthal, which markets immediate and extended formulations of the drug, trademarked Palexia® in various markets in Europe. Janssen has an exclusive license to the drug in the U.S., Canada, and Japan, and another 80 or so markets in Asia Pacific, Latin America, Africa, and some European countries.

Read More →
Share:

The 5th Anniversary Central Asian International exhibition «Chemical industry – Chemie Uzbekistan» and the 2nd Uzbek International exhibition of plastics and rubber – «Plastex Uzbekistan 2011» will be held from the 16th till the 18th of November 2011, at the Pavilion 1 of OJSS «Uzexpocentre».

“ITE UZBEKISTAN” is the organizer of the exhibitions

Talking about Uzbekistan, look at this siteif you would need some oils and herbal essentials to take along with you in the tour. Uzbekistan is a safe country and you can enjoy the serenity and the relaxed atmosphere here. Tashkent is the largest city in Uzbekistan. You can definitely plan your next trip to Uzbekistan, either solo or with family.

Though there is no strict dress code to be followed when visiting Uzbekistan, it is important that you do not wear any revealing dresses. The country folks dress conservatively and it is important that you do so as a respect to their culture. Make sure that you pack comfortable shoes that make it easy to walk on the sandy and dry ground. Long skirts and pants and long sleeve shorts with a high neckline can be worn in Uzbekistan.

The exhibitions will feature the following sections:

– Agrochemistry
– Raw and equipment for chemical industry
– Composite materials, glass-fibre plastics
– Grit-tipped blade
– Synthetic rubbers
– Household chemicals
– Keeping and transporting of chemical product
– Chemical technologies, research activities
– Laboratory and analytical equipment, devices
– Technic and equipment for producing plastics and rubbers
– Equipment for primary processing materials
– Reprocessing equipment
– Extruders and extrusion utilities
– Machines for ?????? ??? blown forming
– Machines and equipments for producing tyres
– Auxiliary equipment, forms, matrix
– Raw and auxiliary materials
– Mechanical packer
– Semi-finished product and ready-made goods
– Services in the sphere of producing fibers and rubbers

New technologies and innovations in the sphere of chemical substance, raw and auxiliary equipments will be presented at the exhibitions as well.

Such companies from Austria, Germany, India, China, Poland, Russia, Taiwan, Uzbekistan as: Asian diamond classic; Oybek otchopar plastik; Korting Gmbh; Nigmatjon-rin; Omsk plant of trumpet isolation; Xinjiang huangjin mid-asia engineering technology co., Ltd; Uzkimyosanoat; Tongling nextool; Tingdao plastic; Qingdao leader; Trade and Investment Promotion Department of the Embassy of the Republic of Poland in the Rebublic pf Uzbekistan; King hsing; Coperion Gmbh; Starlinger; Lohia starlinger; Shurtan g

Read More →
Share:

The inaugural Drug Discovery Latin America conference and exhibition will be held in the colourful city of Rio de Janeiro in the days immediately following the world famous carnival.

The purpose of this meeting is to review the status of drug discovery activities in Latin America and to assist its future development. Drug discovery is an important part of medical science. Thissite web speaks about how the medicines developed in the last century were derived from molecules that were naturally occurring. These are products that are found in the natural sources. Itincludes fungi,bacteria and plants. The drugs are first tested on animals and then it goes through the clinical trials. These are tested on healthy individuals to check if the drugs are safe. Business and research leaders from both developed markets and BRIC countries will bring their knowledge and experience to share. Participants will be encouraged to network and explore partnering opportunities.

Full conference passes include admission to all sessions and the exhibition as well as conference documentation.
Lunch, coffee breaks and the drinks reception provide ample time for networking and to continue discussions from the question and answer sessions.

Agenda

Day One – 26 February 2009

Screening

09:00

Using Drug Molecules as Probes and Probe Molecules as Drug Precursors
Ralph Garippa, Research Leader, Roche Discovery Technologies
This talk will highlight some examples of Pharma’s HT screened molecules which became popular commercialized reagents, and some promising molecules which have been published in the public domain (PubMed) as a result of academic screening.

09:30

Title to be Confirmed
Jeremy Caldwell, Director of Cell Based Screening, GNF

10:00

Using in vitro Screening Assays to Profile the Biology of Chemical Entities
John Watson, Director, Pharmacology and Biotechnology, Promega
Profiling of a compound’s impact on cell signaling pathways, ADME properties and cellular toxicity early in the discovery process can help prioritize compounds to help assure the final drug has maximal target activity and minimal off target effects.

10:30

Coffee and Networking in the Exhibition Hall

11:15

Nuclear Receptor Activation Assessment: Improving Safety and Directing Chemistry
Kyle Kramer, Vice President, Business Development, Puracyp
The presentation includes introduction to key nuclear receptors (NR) involved in drug metabolism. The construction and use of stable cell lines with reporter genes is explained. Finally, the utility of these systems in drug safety screening is presented.

11:45

Functional Genome-Wide Screening for Genes that Regulate p53 in Endothelial Cells
Michael Edel, Principle Investigator, Centre of Regenerative Medicine in Barcelona
Angiogenesis requires an increase in endothelial cell proliferation to support an increase in mass of blood vessels. An in vitro cell model has been designed that can be used for screening gene or chemical libraries that regulate endothelial cell proliferation.

12:15

Presentation to be Announced

12:45

Lunch and Networking in the Exhibition Hall

Tropical Disease Drug Development

14:00

Prolyl Oligopeptidase of Trypanosoma cruzi (POP Tc80) : A Target for the Design of New Weapons Against Chagas Desease
Bernard Maigret, CNRS Research Director, LORIA – Nancy University
The group has recently demonstrated that the activity of POPTc80, a prolyl endopeptidase that mediates native collagen and fibronectin hydrolysis, is required for trypomastigotes entry into host cells. Using a tridimentionnel model of this target built from homology modelling, molecular docking and screening assays they were able to identify possible new compounds active against Chagas desease.

14:30

Novel Drug Targets for the Malaria Parasite
Asif Mohmmed, Staff Research Scientist, International Centre for Genetic Engineering and Biotechnology

15:00

Title to be Confirmed
Leila de Mendonça Lima, Senior Researcher and Head of Lab. for Functional Genomics and Bioinformatics, Oswaldo Cruz Foundation, FIOCRUZ

15:30

Coffee and Networking in the Exhibition Hall

16:15

Drug Discovery of Fluorinated Drugs Against Neglected Diseases and HIV/AIDS
Núbia Boechat, Head of R&D Group in Medicinal Chemistry, Oswaldo Cruz Foundation, FIOCRUZ
Organic synthesis of fluorinated compounds in medicinal chemistry against AIDS and neglected diseases; innovation and technological management in public health.

Drug Discovery in Emerging Markets

16:45

Drug Development and Discovery
Christopher Bianca, Professor of Chemistry, Clinical Consultant, Keystone College Academia
This presentation discusses all the relevant information required to develop a new drug or a lead compound drug, from toxicology, to pharmacodynamics, to pharmacokinetics, and all the way to clinical trials including FDA approval.

17:15

Stem Cells in Drug Discovery
Chris Kendrick-Parker, Chief Commercial Officer, Cellular-Dynamics International

17:45

Drinks Reception

Day Two – 27 February 2009

Drug Discovery in Emerging Markets (continued)

09:00

Title to be Confirmed
Marcelo Criscuolo, Executive Director, Bio Sidus

09:30

Ranbaxy’s Quest to Become a Research Based International Pharmaceutical Company
Abhijit Ray, Director, New Drug Discovery Research, Ranbaxy Laboratories
Ranbaxy has worked hard to create physical infrastructure, science base and a sustainable strategy for drug discovery research. How this effort has borne fruit will be discussed.

10:00

Taking Companies from Concept to Market
Paul Morril, Co-Founder, Execute Technologies

10:30

Coffee and Networking in the Exhibition Hall

11:15

Title to be Confirmed
Jose Krieger, Heart Institute (InCor), University of Sao Paulo

11:45

Comparative Proteomics Identification of Diagnostic and Prognostic Biomarkers in Leukemias
Eliana Abdelhay, Head of the Bone Marrow Transplantation Laboratory, National Cancer Institute (INCA)
Through proteomics the group analyzed the modifications in the protein profile of bone marrow MNCs from patients in CML phases and in Imatinib Mesylate treatment. They could identify several putative biomarkers of diagnostic, evolution and treatment response that can be use in drug design.

12:15

NFAT Transcription Factors: A Putative New Target in Cancer
João Viola, Head, Division of Cell Biology, National Cancer Institute (INCA)
The Nuclear Factor of Activated T Cells (NFAT) family of transcription factors is activated upon different stimuli that lead to increased intracellular calcium levels. NFAT proteins regulate genes that control many aspects of malignant cell transformation and tumour development. The group investigates the molecular mechanisms by which NFAT regulate tumour-related events and its involvement in oncogenesis.

12:45

Lunch and Networking in the Exhibition Hall

Natural Products

14:00

ChemBioBank, an Academic Project for Drug Discovery in Latin America
Fernando Albericio, Executive Director, Barcelona Science Park, University of Barcelona
The goal of the Latin American ChemBioBank project (LA-CBB) is to build a chemico-biological database, annotated with both biological and bioinformatic data, addressed to the scientific community and to the pharmaceutical and biotech industries.

14:30

High Content Screens for Novel Antipoxviral Agents: Natural Products to the Rescue
Hakim Djaballah, Director, Memorial Sloan Kettering Cancer Centre
The group have developed and validated a high content assay to screen for compounds that would preferentially block viral entry, viral replication, or viral spread upon infecting cell monolayer seeded in 384-well plates with a recombinant vaccinia virus which expresses karyophilic GFP under the control of a viral early/late promoter.

15:00

Using a Luciferase Based Screening Assay to Identify Traditional Chinese Medicine Targeting Nuclear Hormone Receptors
Chiwai Wong, Principal Investigator, Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences
Since the activities of nuclear hormone receptors (NHRs) are regulated by small molecule compounds and that Traditional Chinese Medicine (TCM) extracts contain a diverse array of naturally derived chemicals, the group investigated if selective TCM extracts modulate the activities of NHRs.

15:30

Coffee and Networking in the Exhibition Hall

16:15

Bourreria huanita Flowers, a New Antidepressant?
Miguel Torres, Biological Chemist, University of San Carlos
Ethnobotanical and pharmacological studies have preliminarily demonstrated an antidepressant effect in ethanolic extract of dried Bourreria huanita (Boraginaceae) flowers from Guatemala. It’s possible this natural product contains a medically useful molecule and funding is required to continue the chemical analysis and elucidation.

16:45

Post Absorption and Metabolism Compounds: A New Approach to Discover Drug Candidates from Chinese Herbal Medicine
William Jia, VP Research and Associate Professor, Shanghai Innovative Research Centre/University of British Columbia
In a recent study the group has isolated compounds post absorption/metabolism (PAM) of orally taken ginseng. The study showed that those compounds are highly active for neuroprotection and anti-depression.

Read More →
Share:

Genentech this week will step up its efforts to keep the drug Avastin available as a treatment for breast cancer, urging the Food and Drug Administration to give it one more chance to prove the medicine works.

At a hearing on Tuesday and Wednesday in suburban Washington, Genentech will ask the F.D.A. to reconsider its proposal last December to revoke the approval of Avastin for breast cancer on the grounds that new studies did not confirm that the drug helped patients.

Breast cancer can be treated if detected at an early stage. The early signs of breast cancer are a mass or lump on the breast, swelling in a part or all of the breast, dimpling or skin irritation , pain in the nipple or breast, scaly or red breast skin, and discharge from the nipple. You can also treat varicose vein with Varikosetteif diagnosed early.

Genentech’s approach seems intended to broaden the terms under which Avastin can remain available. The company is arguing that even if the F.D.A. reaffirms that data do not support Avastin’s effectiveness, the approval should be retained while Genentech does one more clinical trial. Avastin has remained available for breast cancer pending the appeal process.

Avastin was put on the market under an accelerated program begun in the early 1990s that allows drugs for serious diseases to be approved with less than the usual amount of evidence, subject to further studies. Dozens of drugs have been approved this way, and in at least a couple of cases approvals have been withdrawn. But this is the first time the F.D.A. will hold a hearing to consider a company’s appeal.

The debate over Avastin has evoked passions on both sides among those involved in women’s health issues. Some patient advocates argue that the F.D.A. needs to revoke the approval to maintain the integrity of the accelerated process and to ensure that cancer patients receive drugs that work.

But some breast cancer patients are expected to testify at the hearing that the drug should be kept available because it helps some women, even if not all.

“It’s so depressing to think that a federal agency can make a decision that can potentially cause me to die,” said Crystal Hanna, 35, a mother of two from Parkersburg, W.Va., who said Avastin has kept her cancer under control for almost a year.

The public comments sent to the F.D.A. before the hearing at its campus outside Washington, overwhelmingly support retaining the approval. Many of them, using virtually identical language, cite the case of Ms. Hanna, who drafted a comment for friends that circulated widely on the Internet.

Even if approval as a breast cancer treatment is ultimately rescinded, Avastin will retain approval to treat lung, colon, kidney and brain cancers. So doctors will be able to use it “off label” to treat breast cancer. But insurers might no longer pay for it for that use, putting the drug, which can cost $88,000 a year, out of reach for many women.

The Avastin issue has become caught up in the politics of overhauling health care, with some critics saying the decision not to pay for it represents rationing and others saying that Medicare should not pay for a drug that does not work. The F.D.A. maintains that it is not permitted to consider costs.

The ultimate decision will be made by the F.D.A. commissioner, Dr. Margaret A. Hamburg, who appears to have some latitude. The rules say that the F.D.A. “may” revoke the approval of a drug, but does not have to.

“Even where F.D.A. determines that confirmatory trials do not establish clinical benefit, withdrawal is not required and instead should be based on the public health considerations that motivate the accelerated approval statute,” Genentech argues in a summary of its arguments filed before the hearing.

But the F.D.A.’s drug division views the company’s request as a stalling tactic. “How many bites of the apple do you get?” Dr. Richard Pazdur, the director of the agency’s oncology drug division, said in an interview at a cancer conference early this month.

The agency, in a summary of its arguments, says that because it has already determined that the benefits of Avastin do not outweigh the risks, retaining the approval while the new study is conducted “would not be in the interest of the public health and would jeopardize the integrity of the accelerated approval program.”

Genentech and its parent company, Roche, could lose as much as $1 billion in annual sales if the breast cancer approval were revoked. Already Avastin sales for treatment of breast cancer have started declining. The drug is the world’s best-selling cancer drug, with sales last year of roughly $7 billion.

The F.D.A. approved the drug for advanced breast cancer in February 2008, after one clinical trial showed that combining Avastin with another drug, paclitaxel, delayed the median time before tumors worsened by 5.5 months, compared with using paclitaxel alone. But the women who got Avastin did not live significantly longer than those who got only paclitaxel, which is also known by the brand name Taxol.

Subsequent trials, in which Avastin was combined with different chemotherapy drugs, showed a much smaller delay in tumor progression, ranging from less than 1 month to 2.9 months. And again there was no improvement in survival for those receiving Avastin.

Based on those results and on the fact that Avastin has some life-threatening side effects, including bowel perforation and hemorrhaging, the F.D.A.’s cancer drug advisory committee voted 12 to 1 last July that the approval for the treatment of breast cancer be revoked.

The hearing this week will be before the same committee, which will make recommendations to the F.D.A. commissioner. Of the six voting committee members expected to attend, five voted to revoke the approval last July. The sixth was not at that earlier meeting. Since the data have not changed, Genentech, in the summary of its arguments, concedes it is not likely to change the committee’s mind about the benefits of Avastin.

Instead it will argue that the drug with which Avastin is combined matters. Therefore, the company should be given a chance to do another trial in which Avastin is combined with paclitaxel, as in the original trial that led to the drug’s approval.

Read More →
Share:

Inpharmatica Ltd today announces that Wyeth Pharmaceuticals, a division of Wyeth has licensed Admensa Interactive, Inpharmatica’s platform of predictive drug absorption, distribution, metabolism and excretion models and compound prioritization tools.

Wyeth will use Admensa Interactive to support compound selection and optimization in its drug discovery projects.

This new license, agreed after an extensive evaluation, further demonstrates the value that Admensa Interactive brings to pharmaceutical and biotechnology companies.

Under the terms of the agreement, Wyeth will receive a multi-site license to Admensa Interactive.

The load on the health care system is immense. Many entrepreneurs are venturing into this space. The healthcare business could also be a great idea for your start-up. The healthcare industry is, however, sensitive and you should make sure that you embark on this journey with care.

You know of the immense potential that this business has to offer. You may also decide to make healthcare supplements like Bioretinwhich is an anti-ageing cream.

The industry is prosperous and you being a businessman may want to tap this space. The healthcare industry also has a genuine gesture towards philanthropy. Now that you are determined you should weigh the issues and be prepared before you get into the healthcare sector. Have a strategy that is well thought of and well developed.

Admensa Interactive combines predictive models with a desktop interface combining model output with project data from other sources.

This integrated selection and visualization platform drives effective decisions on the best compounds on which to move forward against project criteria.

Admensa Interactive is a major component of Inpharmatica’s range of gene-to-candidate technologies which integrate biology and chemistry-based drug discovery activities.

Inpharmatica’s platform ranges from target selection based on druggability, through rapid identification of hits to selection of high quality leads and pre-clinical candidates, which are prioritized on the basis of good drug-like characteristics.

“We are delighted that Wyeth has opted for a broad deployment of Admensa Interactive in support of its drug discovery projects,” said Matt Segall, Head of the Admensa Business Unit of Inpharmatica.

“The strong uptake of this product by top pharma and biotech companies is a testimony to the unique capabilities it provides for compound optimization.”

Further Information: http://www.inpharmatica.com/admensa.htm

Read More →
Share:


*** PRESENT A POSTER *** Deadline 2 September 2005. If you would like the opportunity to present your poster at this event, please email abstracts to: v.colcombet@selectconferences.com – LIMITED SPACE AVAILABLE

The inaugural conference on Advances in Microarray Technology provides an in-depth analysis of the current thinking and latest technologies within this field.

Technology is a big boon to the society. It has been beneficial to humans in various ways. In the medical field, technology is used to treat the sick patients more effectively. It also helps to save lives and combat harmful bacteria. Technology brought to us Artrovexwhich is an amazing product that helps to treat joint pain. Technology has increased productivity in almost every industry in the world.

This highly targeted event has captured the imagination of the industry and has proved to be very popular so far. Don’t miss this opportunity to network with the leading institutions from around the world.

Register from only €310

Organisations already confirmed:

Adhesives Research Ireland Ltd – Affymetrix, Inc. – Akonni Biosystems Inc. – Arrayjet – Asterand Inc – Auburn University – Avalon Pharmaceuticals – BioChannel Partners Ltd – BioDiscovery, Inc. – Bioeagles Ltd – Cambridge Life Sciences – Centre de recherché en Infectiologie de l’Universite Laval – Cytomyx – DKFZ Heidelberg – Dynal Biotech Ltd. – Epitome Biosystems, Inc. – European Institute of Oncology – Fluidigm Corp. – Free University of Brussels – Functional Genomics Center Zurich – GSF Research Centre, BIOP – Imperial College London – Innogenetics NV – InsightFaraday Partnership – Institut Curie – Institut des Hautes Etudes Scientifiques & Interdisciplinary Research Institute – Invitrogen Ltd. – KREATECH Biotechnology – Lund University – Max Planck Institute for Marine Microbiology – Metis Biotechnology Ltd – Netherlands Vaccine Institute – NMI Natural and Medical Sciences Institute at the University of Tuebingen – Novartis Pharma AG – PamGene International – Pfizer Inc. – Protagen AG – Royal Insti tute of Technology (KTH) – Schott Janaer Glas GmbH – Serono International – Sterne Kessler Goldstein & Fox – University Medical Center Hamburg-Eppendorf – University of Edinburgh – University of Manchester – University of Pretoria – University of Wageningen – University of Washington – Veterinary Laboratories Agency – ViaLogy Corp. – Whatman/Schleicher & Schuell – Yole Developpement

Exhibitors already confirmed

– Arrayjet – Corporate Sponsor
– Cytomyx – Corporate Sponsor
– Invitrogen Corporation – Corporate Sponsor
– Tecan – Corporate Sponsor
– Agilent Technologies
– Operon
– RZPD
– Davin Optronics Ltd
– GRI
– Genomic Solutions
– KREATECH Technologies
– Miltenyi Biotec GmbH
– Parallabs Ltd
– Schott Nexterion
– Scienion AG
– Sigma-Aldrich
– Topspin APS

Further details available through the following links:

Full Agenda http://www.selectbiosciences.com/conferences/AMT/Detailed_Agenda.aspx

Conference Brochure http://www.selectbiosciences.com/conferences/files/AMT%20brochure.pdf

Registration – Register by August 31st and SAVE UP TO €200 https://selectbiosciences.com/conferences/AMT/booking/register.aspx

===============================================================================================

Agenda Sessions and Speakers:

Day One: 11th October

08:30 THE BIOCHIP BUSINESS
Chaired by Dr. Arndt Benecke, Institut des Hautes Etudes Scientifiques & Interdisciplinary Research Institute

  • Dr. Geraldine Andrieux, Yole Developpement
  • Dr. Jorge Goldstein, Sterne Kessler Goldstein & Fox

————————————

10:30 BIOINFORMATICS
Chaired by Dr. Arndt Benecke, Institut des Hautes Etudes Scientifiques & Interdisciplinary Research Institute

  • Dr. Arndt Benecke, Institut des Hautes Etudes Scientifiques & Interdisciplinary Research Institute
  • Speaker to be confirmed, ViaLogy Corp.
  • Dr. Bruce Hoff, BioDiscovery, Inc.
  • Dr. Eugene Novikov, Institut Curie

————————————

14:05 TISSUE & CELL-BASED MICROARRAYS
Chaired by Prof. Guido Sauter, University Medical Center Hamburg-Eppendorf

  • Prof. Guido Sauter, University Medical Center Hamburg-Eppendorf
  • Dr. Xavier Gidrol, CEA
  • Dr. Roberta Carbone, European Institute of Oncology
  • Dr. Roderick Westrop, Cytomyx
  • Dr. Juan J. Miret, Pfizer Inc.

Day Two: 12th October

08:30 PROTEIN MICROARRAYS: TECHNOLOGY AND APPLICATIONS PART I

Chaired by Prof. Mathias Uhlen, Department of Biotechnology, Albanova University Center, Royal Institute of Technology (KTH), Stockholm

  • Dr. John L. Tonkinson, Epitome Biosystems, Inc.
  • Dr. Ulrike Korf, DKFZ Heidelberg
  • Keynote Speaker – Prof. Mathias Uhlén, Department of Biotechnology, Albanova University Center, Royal Institute of Technology (KTH)
  • Dr. Jens Beator, Whatman/Schleicher & Schuell
  • Dr. Christer Wingren, Lund University
  • Dr. Jeremy Gillespie, Invitrogen Ltd.

————————————

13:55 PROTEIN MICROARRAYS: TECHNOLOGY AND APPLICATIONS PART II

Chaired by Dr. Colin Campbell, The University of Edinburgh

  • Keynote Speaker – Dr. Thomas Joos, NMI Natural and Medical Sciences Institute at the University of Tuebingen
  • Dr. Mike Bunce, Dynal Biotech Ltd.
  • Dr. Charles Daitch, Akonni Biosystems Inc.
  • Dr. Mohammed Zourob, University of Manchester
  • Dr. Colin Campbell, The University of Edinburgh
  • Mr. Duncan J Hall, Arrayjet

Day Three: 13th October

08:30 ADVANCES IN DNA MICROARRAYS
Chaired by Dr. Wolfgang Budach, Novartis Pharma AG

  • Dr. Wolfgang Budach, Novartis Pharma AG
  • Dr. Tarif Awad, Affymetrix, Inc.
  • Dr. Kris Pappaert, Free University of Brussels
  • Dr. Ted van der Lende, KREATECH Biotechnology
  • Dr. Katrin Steinmetzer, Schott Janaer Glas GmbH
  • Dr. Arnold Vainrub, Auburn University

————————————

13:55 MICROFLUIDIC ARRAYS
Chaired by Prof. Martin Dufva, Dept. of Micro & Nanotechnology, Technical University of Denmark

  • Dr. Michael Lucero, Fluidigm Corp.
  • Dr. Rinie van Beuningen, PamGene International
  • Dr. Koen de Smet, Innogenetics NV
  • Dr. Regis Peytavi, Centre de recherché en Infectiologie de l’Universite Laval, Quebec

===============================================================================================

Full Agenda available online at: http://www.selectbiosciences.com/conferences/AMT/Detailed_Agenda.aspx

Preconference Training Course – Applications of Microarrays

10 October 2005

Who should attend?
The course will be suitable for scientists, technicians and engineers. It will be helpful to be familiar with DNA, RNA and proteins to follow the material presented. The course has been designed for people considering working with microarrays and for those who are currently working with some applications of microarrays but want a broader view of additional opportunities.

Course tutor:
Prof. Martin Dufva, University of Denmark.

Full course details: http://www.selectbiosciences.com/conferences/AMT/Training_Course.aspx

===============================================================================================

PRESENT A POSTER – Deadline 2 September 2005. To apply for the opportunity to present at this event, please email abstracts to: v.colcombet@selectconferences.com

In order to ensure the widest possible audience for our speakers, registration fees start at just €310, making this conference an absolute must if you want to see the latest research and equipment in microarray technology whilst networking with your peers.

Best regards
Virginie Colcombet
Conference Manager

Read More →
Share: